Advanced Search
Contact | Corporate | Help

Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer

Sponsors:
  • USC/Norris Comprehensive Cancer Center
  • Hoffmann-La Roche
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
  • Colorectal Cancer
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: bevacizumab, capecitabine, oxaliplatin
Enrollment:
53

Additional information about NCT00159432.


SourceSolution © 2008-2012